Patent Baristas

What: Known by many names within the industry – non-practicing entity (NPE), patent assertion entity (PAE) and most infamously as “patent trolls” – NPEs over the past few years have single-handedly spawned a sub-specialty of patent litigation.  It’s certainly big business.  It’s estimated that the average patent suit involving NPEs results in $122 million in […]

United States Patent and Trademark Office (USPTO), Invent Now® and the National Academy of Inventorsâ„¢ invite you to the Florida Regional Inventors Conference, a great chance to get practical advice from expert USPTO staff and to network with fellow creative entrepreneurs. Space is limited, so click here to register early. The conference will be held […]

The day after the Supreme Court issued its  decision in Mayo v. Prometheus, the USPTO issued a letter to the Patent Examining Corps that provides preliminary guidance to examiners and promises that more detailed guidance is forthcoming. MEMORANDUM DATE:            March 21, 2012 TO:                 Patent Examining Corps FROM:           Andrew H. Hirshfeld, Associate Commissioner […]

As you know, the Supreme Court issued its opinion in Mayo v. Prometheus, an important intellectual property case for biotech.  The Court held that the correlation between blood test results and patient health is not patentable. Under Prometheus, new patents involving correlations between natural phenomena must do more than simply recite the natural correlation and then […]

6th Annual Paragraph IV Disputes Expert Insights on Hatch-Waxman Litigation Strategies for Brand Names and Generics April 24-25, 2012 Workshops: April 23 and 26, 2012 Marriott New York Downtown New York City Each spring, leading pharmaceutical patent litigators for brand name and generic drug companies gather in New York City at American Conference Institute’s (ACI’s) […]

What: The only event where the industry leaders driving the business of biosimilars come together to set the standards shaping the rapidly evolving legal and regulatory landscape. Whether you are on the branded or generic side, you cannot afford to miss this opportunity because you will: Hear directly from the FDA on how they will […]

Legal IQ has  launched a new white paper on Intellectual Property (IP) Portfolio Management Trends and Success Factors 2012, which reviews the recent challenges and changes in IP.  It draws upon the insight of leading legal professionals from across the world, and across Patents and Trademarks. They share how they view the future and plan […]

More commentary on the compulsory license granted by the Indian Patent Office for Bayer’s drug Sorafenib Tosylate (Nexavar): I read your follow-up post on compulsory licensing.  In it, you state that average income in India is $8000.  I have no idea what your source is, but you are regrettably wrong.  Average gross salary in India […]